COMP <GO>
AMRX vs UNH // FORWARD P/E MULTIPLE
Amneal Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: AMRX 6
— UNH 8
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
forward-pe
96.0x
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
forward-pe
17.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 88.31% | -51.41 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 12.38% | +1.72 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | 15.3x | +6.13 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 6.25% | -2.62 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.10% | 5.32% | +7.78 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 3.53% | -1.13 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 3.33% | +4.67 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 3.09 | +0.74 | AMRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 55.1 | -4.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 96.0x | 17.7x | +78.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $359.43B | -$352.31B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | UNH REV | AMRX GROSS % | UNH GROSS % | AMRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $447.57B | 36.9% | 88.7% | $269.9M | $16.07B |
| FY 2024 | $2.79B | $400.28B | 36.5% | 88.3% | $243.2M | $20.70B |
| FY 2023 | $2.39B | $371.62B | — | 89.6% | $237.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
UNH // BETA 0.33